Diabetes and Elevated Hemoglobin A1c Levels Are Associated with Brain Hypometabolism but Not Amyloid Accumulation

Rosebud O. Roberts^{1,2}, David S. Knopman², Ruth H. Cha¹, Michelle M. Mielke¹, V. Shane Pankratz¹, Bradley F. Boeve², Kejal Kantarci³, Yonas E. Geda^{4,5}, Clifford R. Jack, Jr.³, Ronald C. Petersen^{1,2}, and Val J. Lowe³

¹Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota; ²Department of Neurology, Mayo Clinic, Rochester, Minnesota; ³Department of Radiology, Mayo Clinic, Rochester, Minnesota; ⁴Department of Psychiatry and Psychology, Mayo Clinic, Scottsdale, Arizona; and ⁵Department of Neurology, Mayo Clinic, Scottsdale, Arizona

Dysfunctional insulin signaling may affect brain metabolism or amyloid deposition. We investigated the associations of type 2 diabetes with amyloid accumulation measured using ¹¹C-Pittsburgh compound B (¹¹C-PiB) and brain hypometabolism measured using ¹⁸F-FDG PET.

Methods: We studied a sample of nondemented participants from the population-based Mayo Clinic Study of Aging. All subjects underwent MR imaging, amyloid PET, and ¹⁸F-FDG PET. Alzheimer disease (AD) signature and region-of-interest (ROI) measures for ¹¹C-PiB retention ratio and ¹⁸F-FDG ratio were measured. Diabetes was assessed from the Rochester Epidemiology Project medical records linkage system.

Results: Among 749 participants (median age, 79.0 y; 56.5% men, 81.0% cognitively normal; 20.6% diabetic individuals), ¹⁸F-FDG hypometabolism (¹⁸F-FDG ratio < 1.31) in the AD signature meta-ROI was more common in diabetic individuals (48.1%) than in nondiabetic individuals (28.9%; $P < 0.001$). The median ¹⁸F-FDG ratio was lower in diabetic individuals than in nondiabetic individuals in the AD signature meta-ROI (1.32 vs. 1.40, $P < 0.001$) and in the angular (1.40 vs. 1.48, $P < 0.001$) and posterior cingulate gyri ROIs (1.63 vs. 1.72, $P < 0.001$). The odds ratio (OR) for abnormal AD signature ¹⁸F-FDG hypometabolism was elevated (2.28; 95% confidence interval [CI], 1.56–3.33) in diabetic individuals versus nondiabetic individuals after adjustment for age, sex, and education and after additional adjustment for apolipoprotein ε4 allele, glycemic level, and cognitive status (OR, 1.69; 95% CI, 1.10–2.60). However, the AD signature ¹¹C-PiB retention ratio was similar in diabetic individuals versus nondiabetic individuals (OR, 1.03; 95% CI, 0.71–1.51; $P = 0.87$). In post hoc analyses in nondiabetic individuals, a 1% increase in hemoglobin A1c was associated with greater AD signature hypometabolism in cognitively normal subjects (OR, 1.93; 95% CI, 1.03–3.62; $P = 0.04$) and in the total cohort (OR 1.59; 95% CI, 0.92–2.75; $P = 0.10$). **Conclusion:** Diabetes and poor glycemic control in nondiabetic individuals may enhance glucose hypometabolism in AD signature regions. These factors should be investigated in longitudinal studies for their role in detecting onset of symptoms in AD.

Key Words: diabetes; cerebral glucose metabolism; ¹⁸F-FDG PET imaging; ¹¹C-PiB PET imaging; hemoglobin A1c; amyloid accumulation

J Nucl Med 2014; 55:759–764

DOI: 10.2967/jnumed.113.132647

Several studies have reported associations of type 2 diabetes with cognitive impairment, Alzheimer disease (AD), or vascular dementia (1–5). The exact mechanisms underlying the association of diabetes with AD remain incompletely understood, but studies suggest that ischemic cerebrovascular disease and hippocampal atrophy are involved (6–10). Other potential mechanisms including global and regional brain hypometabolism (6,10) and amyloid deposition have been hypothesized (11) but require further investigation. Neuropathologic studies, which provide the gold standard for AD pathology, have been inconsistent; some studies have reported greater amyloid-related pathology in diabetic brains (11) whereas others have not (3,7,12,13). Given the dysfunctional insulin signaling in type 2 diabetes, we hypothesized that abnormal cerebral glucose metabolism in diabetic individuals may lead to neuronal injury and cognitive impairment (14). PET offers the opportunity to study in vivo markers of both abnormal brain metabolism and amyloid accumulation.

The objective of our study, therefore, was to specifically examine the association of type 2 diabetes with in vivo markers of amyloid accumulation and cerebral glucose metabolism measured using ¹¹C-Pittsburgh compound B (¹¹C-PiB) PET and ¹⁸F-FDG PET, in a subset of participants from the population-based Mayo Clinic Study of Aging.

MATERIALS AND METHODS

Study Participants

The study design and methodology have previously been published (15). Briefly, participants were Olmsted County, Minnesota, residents aged 70–89 y on October 1, 2004, who were randomly selected from an enumeration of the population using the Rochester Epidemiology medical records linkage system and invited to participate in the Mayo Clinic Study of Aging (16). Starting in 2008, additional subjects were recruited continually to maintain the sample size. Participants were invited to undergo MR imaging of the brain in 2005 and PET imaging in 2006. All subjects signed a written informed consent form that included the Health Insurance Portability and Accountability Act authorization to use and disclose protected health information. The Mayo Clinic and Olmsted Medical Center Institutional Review Boards approved all study protocols.

Assessment of Cognitive Status

Each participant underwent a nurse or study coordinator interview, a physician evaluation, and cognitive testing by a psychometrist. The interview included questions about memory (participant) and the Clinical Dementia Rating Scale (17) and Functional Activities Questionnaire (informant) (18). The physician evaluation included the Short Test of Mental Status (19) and a neurologic examination. The cognitive testing used 9 tests to assess performance in memory (3 tests), executive function (2 tests), language (2 tests), and visuospatial skills (2 tests) domains.

Received Sep. 17, 2013; revision accepted Nov. 13, 2013.

For correspondence contact: Rosebud O. Roberts, Department of Health Sciences Research, Mayo Clinic, 200 First St. SW, Rochester, MN 55905.

E-mail: roberts.rosebud@mayo.edu

Published online Mar. 20, 2014.

COPYRIGHT © 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

TABLE 1
Characteristics of Participants by Type 2 Diabetes

Characteristic	Type 2 diabetes (n = 154)	No diabetes (n = 595)	P
Age (y)	80.3 (75.8–84.1)	78.9 (75.0–83.5)	0.18
Male sex	96 (62.3)	327 (55.0)	0.10
Education (y)	13 (12–16)	14 (12–16)	0.04
APOE ε4 carrier*	40 (26.0)	160 (26.9)	0.81
PET studies			
AD signature meta-ROI ¹⁸ F-FDG < 1.31†	74 (48.1)	172 (28.9)	<0.001
AD signature meta-ROI ¹⁸ F-FDG ratio	1.32 (1.25–1.46)	1.40 (1.29–1.49)	0.0001
Posterior cingulate ¹⁸ F-FDG	1.63 (1.53–1.75)	1.72 (1.59–1.83)	<0.001
Temporal gyrus ¹⁸ F-FDG	1.10 (1.00, 1.23)	1.15 (1.04, 1.26)	0.05
Angular gyrus ¹⁸ F-FDG	1.40 (1.30–1.53)	1.48 (1.37–1.60)	<0.001
Whole-brain meta-ROI ¹⁸ F-FDG	1.38 (1.31–1.44)	1.43 (1.36–1.49)	<0.001
AD signature meta-ROI ¹¹ C-PiB > 1.50‡	56 (36.4)	209 (35.1)	0.77
AD signature meta-ROI ¹¹ C-PiB	1.39 (1.33–1.75)	1.39 (1.31–1.75)	0.30
Anterior cingulate ¹¹ C-PiB	1.49 (1.41–1.90)	1.45 (1.37–1.83)	0.01
Posterior cingulate/precuneus ¹¹ C-PiB	1.48 (1.39–1.94)	1.45 (1.36–1.87)	0.07
Whole-brain meta-ROI ¹¹ C-PiB	1.39 (1.34–1.67)	1.39 (1.32–1.66)	0.14
Fasting blood glucose (mg/dL)	114.5 (101–131)	97 (90–105)	<0.001
Years in study	4.04 (2.53–6.35)	4.04 (2.56–6.49)	0.36
MCI (n)	40 (29.9)	102 (19.2)	0.007

*One subject in no-diabetes group had missing data.

†AD signature ¹⁸F-FDG ratio.

‡AD signature ¹¹C-PiB ratio.

Estimates are n, with percentages in parentheses, or median, with interquartile ranges in parentheses.

Cognitive domain scores were computed from age-adjusted test scores that were scaled (mean, 10; SD, 3), then summed and scaled tests within a domain to allow comparisons across domains (15,20,21).

Mild cognitive impairment (MCI) criteria were defined as cognitive concern (subject, informant, nurse, or physician), impairment in one cognitive domain or more, essentially normal functional activities, and no dementia (15,21,22). Dementia was based on the *Diagnostic and Statistical Manual of Mental Disorders*, 4th ed. (DSM-IV) (23) criteria. Subjects who performed within the range for cognitively normal (CN) subjects from the population and did not meet criteria for MCI or dementia were considered CN (15,21,22).

Ascertainment of Type 2 Diabetes

Type 2 diabetes was abstracted from the medical records (16) as treatment for diabetes (oral antidiabetic agents, insulin), or a fasting blood glucose of 126 mg/dL or more reported two or more times, or a physician diagnosis (24).

Other Covariates

Date of birth and years of education were assessed by interview. Hemoglobin A1c (HBA1c) level at enrollment was assessed from the medical record (16). Apolipoprotein (APOE) genotype was performed at baseline, and blood glucose was measured just before PET imaging.

¹⁸F-FDG PET and ¹¹C-PiB PET Acquisition

MR imaging was performed at 3T with a 3-dimensional volumetric T1-D-MPRAGE (magnetization-prepared rapid gradient-echo) sequence previously described (25). PET images were acquired using a PET/CT scanner operating in 3-dimensional mode (26). A CT image was obtained for attenuation correction. The ¹¹C-PiB PET scan consisted of four 5-min dynamic frames acquired 40–60 min after injection (27). Subjects were injected with ¹⁸F-FDG 1 h after the ¹¹C-PiB scan and imaged after 30–38 min, for an 8-min image acquisition of four 2-min dynamic frames (27,28). An in-house fully automated image-processing pipeline was used for quantitative image analysis for ¹¹C-PiB and ¹⁸F-FDG. Each subject's PET images were registered to his or her MR

images, which had been labeled with our parcellation atlas (27). An AD signature cortical ¹¹C-PiB PET meta-region-of-interest (meta-ROI) retention ratio was calculated from the median uptake over voxels in the prefrontal, orbitofrontal, parietal, temporal, anterior cingulate, and posterior cingulate/precuneus ROIs normalized to the cerebellar gray matter ROI of the atlas (26). An AD signature ¹⁸F-FDG PET ratio was calculated in a similar manner based on glucose metabolic rates from an Alzheimer signature meta-ROI and consisted of the average bilateral angular gyri, posterior cingulate/precuneus, and inferior temporal cortical ROIs from both hemispheres normalized to pons uptake (29–31).

Statistical Analyses

We defined an abnormal AD signature meta-ROI ¹¹C-PiB retention ratio (standardized uptake value ratio) as greater than 1.50 and an abnormal AD signature meta-ROI ¹⁸F-FDG ratio as less than 1.31, corresponding to the 90% sensitivity in AD dementia (28,32). For ¹¹C-PiB PET, for which higher biomarker values are worse, the cutpoint corresponding to 90% sensitivity was at the 10th percentile of the AD distribution. For ¹⁸F-FDG PET, for which lower biomarker values are worse, the cutpoint was at the 90th percentile of the AD distribution. We examined the association of diabetes with abnormal AD signature ¹¹C-PiB PET ratio and ¹⁸F-FDG PET ratio using logistic regression models adjusted for age and sex. Given that ¹⁸F-FDG ratio varies with cognitive status, we performed analyses for the total sample, MCI, and CN (30). We examined potential confounding and effect modification (interaction) by APOE ε4 allele, blood glucose at PET imaging, and cognitive status. For comparison, we selected non-AD regions of the primary sensorimotor regions and global whole brain (based on 35 ROIs), computed unadjusted and glucose-adjusted means of ¹⁸F-FDG ratio, and examined their associations with diabetes using linear regression models. We conducted post hoc analyses in nondiabetes to determine whether glycemic control (HBA1c) was also associated with hypometabolism. All analyses were conducted using SAS (version 9.3; SAS). P values were considered significant at an α less than 0.05 (2-tailed tests).

FIGURE 1. Box plots for ^{18}F -FDG and ^{11}C -PiB retention ratio in AD signature regions by diabetes mellitus (DM) in CN and MCI subjects. ● = women; ○ = men.

RESULTS

Table 1 shows the characteristics of 749 participants without dementia who underwent PET imaging (2006–2012). The frequency of an abnormal AD signature meta-ROI ^{18}F -FDG ratio was significantly higher among diabetic individuals; the median was lower in diabetic individuals than in nondiabetic individuals in both CN and MCI subjects (Fig. 1, top) and in the total sample (not shown). ^{18}F -FDG hypometabolism was found in all 3 subregions of the AD signature meta-ROI. Unadjusted means for AD signature ^{18}F -FDG ratio for sensorimotor regions and whole brain and were significantly different in diabetic individuals versus nondiabetic individuals, but glucose-adjusted means did not differ (Supplemental Table 1; supplemental materials are available at <http://jnm.snmjournals.org>).

In the total sample, AD signature meta-ROI ^{18}F -FDG ratio was significantly lower in younger diabetic individuals than in nondiabetic individuals (Figs. 2A and 2B), in men than in women (Figs. 2C and 2D), and in APOE $\epsilon 4$ noncarriers than in carriers (Figs. 2E and 2F); the findings were consistent for CN and MCI (not shown). In representative scans, AD signature ^{18}F -FDG hypometabolism was absent in subjects with no diabetes and no MCI (Fig. 3A), minimal in nondiabetic individuals with MCI (Fig. 3B), and worst in diabetic individuals with MCI (Figs. 3C and 3D).

By contrast, the proportion of diabetic individuals versus nondiabetic individuals with an abnormal AD signature meta-ROI ^{11}C -PiB ratio did not differ (Table 1). The median AD signature meta-ROI ^{11}C -PiB ratio was similar for diabetic individuals versus nondiabetic individuals (Table 1) among CN and MCI (Fig. 1, bottom).

Association of Diabetes with AD Signature ^{18}F -FDG Uptake

Diabetes was significantly associated with AD signature meta-ROI ^{18}F -FDG hypometabolism of the range seen in AD dementia (Table 2). The odds ratio (OR) decreased slightly after adjustment for glucose but remained significant for the total sample and MCI cases for the fully adjusted models. Diabetes was associated with decreased ^{18}F -FDG ratio in the sensorimotor ROIs and the whole brain, but the associations were not significant after adjustment for glucose (Supplemental Table 2). There were no significant interactions of diabetes with age, sex, or APOE $\epsilon 4$; the OR for diabetes and hypometabolism was significant for subjects with glucose levels less than 126 mg/dL (OR, 1.72; 95% confidence interval, 1.11–2.69; $P = 0.02$) (Supplemental Table 3).

Association of Diabetes with AD Signature ^{11}C -PiB

In contrast to unadjusted estimates, the OR for abnormal AD signature meta-ROI ^{11}C -PiB was significantly reduced in subjects with MCI after adjustment for age, sex, and education but not after adjustment for APOE $\epsilon 4$ allele (Table 3).

HbA1c and AD Signature ^{18}F -FDG Hypometabolism

In CN nondiabetic individuals, the OR for hypometabolism in the AD signature meta-ROI increased with each 1% increase in HbA1c after adjustment for age, sex, and education (OR, 1.93; 95% CI, 1.03–3.62; $P = 0.04$) and after additional adjustment for APOE $\epsilon 4$ allele (OR, 1.89; 95% CI, 1.00–3.57; $P = 0.049$).

DISCUSSION

In this sample of elderly persons, diabetes was associated with ^{18}F -FDG hypometabolism. This association persisted in the AD signature region for the total sample and MCI cases even after controlling for serum glucose but not in the sensorimotor cortex. By contrast, diabetes was not associated with increased ^{11}C -PiB retention ratio (amyloid accumulation) in AD signature meta-ROIs for the total sample, or for CN subjects, but the OR was significantly reduced in subjects with MCI in models that did not include APOE $\epsilon 4$.

Glucose hypometabolism in diabetic individuals suggests that diabetes affects cerebral energy metabolism independently of amyloid deposition, possibly through mechanisms that cause neuronal injury (33). This hypometabolism in CN diabetic individuals suggests that neuronal injury is present even before symptomatic evidence of cognitive impairment. The loss of significance in the CN group after adjustment for glucose level, however, suggests that the effect of diabetes may be small in CN or below the threshold for sustained effect, such that a larger sample of CN is required to detect a significant difference. Alternately, the findings in CN may be due to a more generalized diabetes effect rather than a specific AD meta-ROI effect. The persistence of significant associations for the total sample and for MCI cases, even after adjustment for glucose, suggests the effect may be real.

FIGURE 2. Box plots of ^{18}F -FDG ratio in AD signature regions in total sample by diabetes (DM) status stratified by age (70–79 y [A] and 80–89 y [B]), sex (women [C] and men [D]), and apolipoprotein $\epsilon 4$ allele ($\epsilon 4$ carrier [E] and $\epsilon 4$ noncarrier [F]). ● = women; ○ = men.

FIGURE 3. ^{18}F -FDG scans for participants without diabetes (CN [A] and MCI [B]) and with diabetes (both with MCI [C and D]). Each image set represents 3-dimensional stereotactic surface projections of regional hypometabolism normalized to age-appropriate healthy subjects and displayed as z score; upper boundary as 7.0 (red) and lower boundary as 0.0 (black). z score of 1.5 (medium blue) or greater would be considered significant.

The stronger association for MCI subjects suggests that hypometabolism may be in the causal pathway for cognitive impairment in diabetic individuals. Finally, the absence of an effect in multivariable models for the sensorimotor cortex suggests that the associations are not entirely explained by a competitive inhibition of labeled glucose uptake by elevated serum glucose in diabetic individuals.

Our subgroup analyses showed stronger associations of diabetes with hypometabolism for APOE $\epsilon 4$ noncarriers, younger subjects, and men. The stronger OR for APOE $\epsilon 4$ noncarriers suggests that APOE $\epsilon 4$ allele effects might share some mechanistic commonalities with diabetes, that are independent of APOE $\epsilon 4$ -related amyloidosis (34). The stronger association in 70- to 79-y-olds may relate to earlier diabetes onset, age-related differences in diabetes effects, nonparticipation in older subjects, or potential survival bias. The stronger OR in men suggests etiologic differences as observed for amnesic MCI in our previous studies (21,35). Follow-up of the cohort will provide greater power to detect significant interactions.

Our findings for HbA1c in nondiabetic individuals support our hypothesis that altered glycemic control is associated with neuronal injury and are consistent with other studies. In CN adults with newly diagnosed prediabetes or diabetes, increasing insulin resistance was associated with greater ^{18}F -FDG hypometabolism in AD regions (36), and higher fasting glucose levels in CN nondiabetic individuals were associated with ^{18}F -FDG hypometabolism (37). These findings suggest that markers of prediabetes should be examined for early detection of brain hypometabolism.

The analyses reported here did not use partial-volume correction. When we applied partial-volume correction, our findings changed somewhat. Significant associations persisted with adjustment for age- and sex-adjusted models in AD signature regions. However, glucose-adjusted models were not significant. This difference in results may mean that the ^{18}F -FDG changes we observed may in part reflect loss of brain volume due either to diabetes or to other etiology. Alternately, we recognize that if diabetes and related hyperglycemia contributes to structural and metabolic changes, controlling for blood glucose may result in overcontrolling.

The absence of an association of diabetes with ^{11}C -PiB retention ratio in AD signature regions in CN subjects is consistent with findings from several studies (3,7,12,13,38). In one study, diabetes was associated with cerebral infarctions but not with AD pathology

TABLE 2
Association of Type 2 Diabetes with Abnormal ^{18}F -FDG PET Ratio* in AD Signature Meta-ROI

Group	Covariates included in each model						Full model 2†
	Age and sex	Education	APOE ε4	Glucose	Cognition	Full model 1†	
Total sample							
OR	2.24	2.28	2.26	1.73	2.17	1.78	1.69
95% CI	1.54–3.27	1.56–3.33	1.55–3.30	1.13–2.63	1.48–3.18	1.17–2.72	1.10–2.60
P	<0.001	<0.001	<0.001	0.01	<0.001	0.008	0.02
CN							
OR	2.21	2.22	2.20	1.50	NA	1.50	NA
95% CI	1.42–3.43	1.43–3.45	1.42–3.41	0.91–2.49		0.91–2.49	
P	0.0004	0.0004	0.0005	0.12		0.12	
MCI							
OR	2.02	2.22	2.31	1.96	NA	2.62	NA
95% CI	0.93–4.41	1.00–4.92	1.03–5.18	0.85–4.51		1.08–6.38	
P	0.08	0.05	0.04	0.11		0.03	

*AD signature meta-ROI ^{18}F -FDG ratio < 1.31.

[†]All models include adjustment for age and sex; columns 3–6 show variables added separately to model with age and sex. Full model 1 is adjusted for age, sex, education, APOE $\epsilon 4$ allele, and glucose level. Full model 2 includes variables in full model 1 and cognition (MCI or normal cognition).

(7); another study found no difference in AD pathology among diabetic individuals and nondiabetic individuals (3). A third study reported that diabetic APOE $\epsilon 4$ carriers had a lower amyloid β load than nondiabetic individuals (12). In contrast, one study reported that diabetic APOE $\epsilon 4$ carriers had greater AD pathology (11), and another reported greater plaque density with longer duration of diabetes (3).

The absence of an association of diabetes with AD signature ^{11}C -PiB ratio and the significantly lower AD signature ^{11}C -PiB in diabetic MCI subjects are inconsistent with the hypothesis that diabetes contributes to increased amyloid deposition (39,40). However, they are consistent with other studies (41). In the Baltimore Longitudinal Study of Aging, diabetes-related parameters were not associated with AD pathology (41). It is possible that diabetes may have greater effects on neuronal injury and brain atrophy than

on amyloid accumulation in elderly persons (8,9). The null association may also be due to interactions of timing of onset of vascular pathology with amyloid deposition in diabetic individuals. By contrast, subjects with diabetes and ^{11}C -PiB deposition occurring independently at earlier ages may progress more rapidly from MCI to dementia and may be less likely to be captured in our cohort because we did not initially enroll demented subjects to imaging studies. The absence of a significant difference in AD signature ^{11}C -PiB ratio for MCI diabetic individuals and nondiabetic individuals (Fig. 1, lower) versus the significant association observed in multivariable models suggests possible confounding; the association was significant after adjustment for age, sex, and education but not APOE $\epsilon 4$ allele. These findings indicate the need to account for potential confounders when comparing ^{18}F -FDG ratio across regions.

One potential limitation of our study is that because of the cross-sectional design, we cannot assess causality. The absence of associations of diabetes with AD signature ^{18}F -FDG ratio in APOE $\epsilon 4$ carriers and with AD signature ^{11}C -PiB retention ratio could be due to underrepresentation of diabetic individuals, lower participation of diabetic individuals with more severe or longer disease duration, or lower frequency of APOE $\epsilon 4$ allele in this older age group. HBA1c was assessed at enrollment and not at the time of imaging; however, the findings support our hypothesis that impaired glucose metabolism affects brain metabolism. Ongoing recruitment should increase the number of diabetic individuals in our sample. Finally, more than 98% of our cohort is of northern European ancestry, thus our findings should be confirmed in other ethnicities.

Our study has several important strengths. Participants were randomly selected from the population; thus, our findings are less subject to selection or volunteer bias. The diagnosis of diabetes was reliably ascertained using the medical records linkage system and not subject to recall bias as occurs with self-reporting. We had a large sample size of subjects who had undergone PET imaging, which provides more reliable estimates than studies of small sample size.

CONCLUSION

In elderly persons, diabetes and impaired glucose metabolism in CN might contribute to neuronal injury. These factors should be

TABLE 3
Associations of Type 2 Diabetes with Abnormal ^{11}C -PiB PET Retention Ratio* in AD Signature Meta-ROI

Group	Covariates included in each model [†]			
	Age and sex	Education	APOE $\epsilon 4$	Full model
Total sample				
OR	1.02	1.03	1.05	1.06
95% CI	0.70–1.49	0.71–1.51	0.70–1.57	0.71–1.59
P	0.91	0.87	0.82	0.78
CN				
OR	1.26	1.28	1.26	1.28
95% CI	0.82–1.95	0.83–1.97	0.80–1.99	0.81–2.02
P	0.30	0.27	0.32	0.29
MCI				
OR	0.39	0.39	0.46	0.46
95% CI	0.17–0.88	0.17–0.90	0.18–1.16	0.18–1.16
P	0.02	0.03	0.10	0.10

*AD signature ^{11}C -PiB ratio > 1.50.

[†]All models include adjustment for age and sex; columns 3 and 4 show variables added separately to model with age and sex. Full model is adjusted for age, sex, education, and APOE $\epsilon 4$ allele.

examined in future longitudinal studies for their potential role in detecting onset of AD symptoms.

DISCLOSURE

The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734. This work was supported by NIH grants U01 AG006786, P50 AG16574, K01 AG028573, K01 MH68351, R01 AG011378, and R01 AG041851; the Robert H. and Clarice Smith and Abigail Van Buren Alzheimer’s Disease Research Program; the Center for Individualized Medicine of Mayo Clinic; the Minnesota Partnership for Biotechnology and Medical Genomics; GE Healthcare; the Elsie and Marvin Dekelboum Family Foundation; the Rochester Epidemiology Project (R01 AG034676); Abbvie Health Economics and Outcomes Research; the Walter S. and Lucienne Driskill Foundation; Cephalon, Inc.; Allon Therapeutics, Inc.; the NIA; the Alzheimer’s Association; the Mangurian Foundation; the Alexander Family Alzheimer’s Disease Research Professorship; Siemens Molecular Imaging; the MN Partnership for Biotechnology and Medical Genomics; and the Leukemia & Lymphoma Society. Dr. Knopman is deputy editor for *Neurology*; on the data safety monitoring boards for Lilly Pharmaceuticals, Lundbeck Pharmaceuticals, and the DIAN study; a consultant to TauRx Pharmaceuticals through 2012; and an investigator for clinical trials by Baxter and Elan Pharmaceuticals, TauRx. Dr. Kantarci is on the data safety monitoring board for Takeda Global Research & Development Center, Inc. Dr. Boeve is a consultant to GE Healthcare and receives publishing royalties for *The Behavioral Neurology of Dementia* (Cambridge University Press, 2009). Dr. Petersen is on the scientific advisory boards for Pfizer, Inc., Janssen Alzheimer Immunotherapy, Elan Pharmaceuticals, and GE Healthcare; is a CME lecture for Novartis, Inc.; and receives royalties for *Mild Cognitive Impairment* (Oxford University Press, 2003). Dr. Jack is a consultant for Janssen, Bristol-Meyer-Squibb, General Electric, Siemens, and Johnson and Johnson and an investigator for Allon and Baxter, Inc., clinical trials. Dr. Lowe is on the scientific advisory boards for Bayer Schering Pharma and GE Healthcare. No other potential conflict of interest relevant to this article was reported.

REFERENCES

- Akomolafe A, Beiser A, Meigs JB, et al. Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. *Arch Neurol*. 2006;63:1551–1555.
- Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. *Arch Neurol*. 2004;61:661–666.
- Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. *Diabetes*. 2004;53:474–481.
- MacKnight C, Rockwood K, Awalt E, McDowell I. Diabetes mellitus and the risk of dementia, Alzheimer’s disease and vascular cognitive impairment in the Canadian Study of Health and Aging. *Dement Geriatr Cogn Disord*. 2002;14:77–83.
- Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort. *Am J Epidemiol*. 2001;154:635–641.
- Debette S, Seshadri S, Beiser A, et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. *Neurology*. 2011;77:461–468.
- Arvanitakis Z, Schneider JA, Wilson RS, et al. Diabetes is related to cerebral infarction but not to AD pathology in older persons. *Neurology*. 2006;67:1960–1965.
- Marchant NL, Reed BR, Sanossian N, et al. The aging brain and cognition: contribution of vascular injury and $\alpha\beta$ to mild cognitive dysfunction. *JAMA Neurol*. 2013;70:488–495.
- Chui HC, Zarow C, Mack WJ, et al. Cognitive impact of subcortical vascular and Alzheimer’s disease pathology. *Ann Neurol*. 2006;60:677–687.
- Cherbuin N, Sachdev P, Anstey KJ. Higher normal fasting plasma glucose is associated with hippocampal atrophy: the PATH Study. *Neurology*. 2012;79:1019–1026.
- Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. *Diabetes*. 2002;51:1256–1262.
- Alafuzoff I, Aho L, Helisalmi S, Mannervaa A, Soininen H. Beta-amyloid deposition in brains of subjects with diabetes. *Neuropathol Appl Neurobiol*. 2009;35:60–68.
- Heitner J, Dickson D. Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects: a retrospective postmortem immunocytochemical and histofluorescent study. *Neurology*. 1997;49:1306–1311.
- Duarte AI, Moreira PI, Oliveira CR. Insulin in central nervous system: more than just a peripheral hormone. *J Aging Res*. 2012;2012:384017.
- Roberts RO, Geda YE, Knopman DS, et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. *Neuroepidemiology*. 2008;30:58–69.
- St. Sauver JL, Grossardt BR, Yawn BP, Melton LJ III, Rocca WA. Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester Epidemiology Project. *Am J Epidemiol*. 2011;173:1059–1068.
- Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. *Neurology*. 1993;43:2412–2414.
- Pfeffer RI, Kurosaki TT, Harrah CH Jr, Chance JM, Filos S. Measurement of functional activities in older adults in the community. *J Gerontol*. 1982;37:323–329.
- Kokmen E, Smith GE, Petersen RC, Tangalos E, Ivnik RC. The short test of mental status. Correlations with standardized psychometric testing. *Arch Neurol*. 1991;48:725–728.
- Ivnik RJ, Malec JF, Smith GE, et al. Mayo’s older Americans normative studies: WAIS-R, WMS-R and AVLT norms for ages 56 through 97. *Clin Neuropsychol*. 1992;6(suppl):1–30, 49–82, 83–104.
- Petersen RC, Roberts RO, Knopman DS, et al. Prevalence of mild cognitive impairment is higher in men: the Mayo Clinic Study of Aging. *Neurology*. 2010;75:889–897.
- Petersen RC. Mild cognitive impairment as a diagnostic entity. *J Intern Med*. 2004;256:183–194.
- American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders: DSM-IV*. 4th ed. Washington, DC: American Psychiatric Association; 1994.
- Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2003;26:S5–S20.
- Jack CR Jr, Bernstein MA, Fox NC, et al. The Alzheimer’s Disease Neuroimaging Initiative (ADNI): MRI methods. *J Magn Reson Imaging*. 2008;27:685–691.
- Lowe VJ, Kemp BJ, Jack CR Jr, et al. Comparison of ^{18}F -FDG and PiB PET in cognitive impairment. *J Nucl Med*. 2009;50:878–886.
- Jack CR Jr, Lowe VJ, Senjem ML, et al. ^{11}C PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnesic mild cognitive impairment. *Brain*. 2008;131:665–680.
- Knopman DS, Jack CR Jr, Wiste HJ, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. *Neurology*. 2012;78:1576–1582.
- Landau SM, Harvey D, Madison CM, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. *Neurobiol Aging*. 2011;32:1207–1218.
- Jagust WJ, Landau SM, Shaw LM, et al. Relationships between biomarkers in aging and dementia. *Neurology*. 2009;73:1193–1199.
- Landau SM, Harvey D, Madison CM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. *Neurology*. 2010;75:230–238.
- Jack CR, Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging–Alzheimer’s Association criteria for preclinical Alzheimer disease. *Ann Neurol*. 2012;71:765–775.
- Knopman DS, Jack CR Jr, Wiste HJ, et al. Brain injury biomarkers are not dependent on β -amyloid in normal elderly. *Ann Neurol*. 2012;73:472–480.
- Jagust WJ, Landau SM. Apolipoprotein E, not fibrillar β -amyloid, reduces cerebral glucose metabolism in normal aging. *J Neurosci*. 2012;32:18227–18233.
- Roberts RO, Geda YE, Knopman DS, et al. The incidence of MCI differs by subtype and is higher in men: The Mayo Clinic Study of Aging. *Neurology*. 2012;78:342–351.
- Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. *Arch Neurol*. 2011;68:51–57.
- Burns CM, Chen K, Kaszniak AW, et al. Higher serum glucose levels are associated with cerebral hypometabolism in Alzheimer regions. *Neurology*. 2013;80:1557–1564.
- Petrovitch H, White LR, Izmirlian G, et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia Aging Study. *Neurobiol Aging*. 2000;21:57–62.
- Qiu WQ, Folstein MF. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer’s disease: review and hypothesis. *Neurobiol Aging*. 2006;27:190–198.
- Hoyer S. The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update. *J Neural Transm*. 2002;109:341–360.
- Thambisetty M, Metter EJ, Yang A, et al. Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore Longitudinal Study of Aging. *JAMA Neurol*. 2013;70:1167–1172.